atepeq/tico19 huggingface dataset:
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
Naqdin baahsan oo lagu sameeyay samaynta xarunta caafimaadka ee COVID-19 talaalkiisa iyo dawooyinka la sameeyay, Abriil 2020. Dhawr dawo oo hore oo fayrusyada ah ayaa la eegey in lagu daweeyo COVID-19, oo ay ku jiraan remdesivir, chloroquine iyo hyroxychloroquine, lopinavir/ritonavir iyo lopinavir/ritonavir lagu daray interferon beta.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
Cadaymayan waxaa lagu eegayaa hoos u dhaca remdesivir, ilaa Maarso 2020.
There is tentative evidence for efficacy by remdesivir, as of March 2020.
Waxaa la arkay caafimaadka oo kasoo raynaya ee bukaanka markii la isticmaalay si naxariis leh remdesivir.
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
Wajiga III tijaabada xarunta caafimaadka ayaa lagu sameeyay Maraykanka, Jayna, iyo Talyaaniga. Chloroquine, hore loogu isticmaalay daawanta maraaliyada, daraasad lagu sameeyay Jayna Febraayo, 2020, taas oo natiijadeeda hordhaca ahi ay soo baxday.
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
Laakiin, waxaa jira baaq in an cilmi baadhayaasha dhigooda ahi ay eegaan.
However, there are calls for peer review of the research.
Maamulka Caafimaadka Kuuriya iyo Jayna waxay ku taliyaan isticmaalka chloroquine.
Korean and Chinese Health Authorities recommend the use of chloroquine.
Laakiin, Hay'ada Wuhan ee Fayrusyada, in kasta oo ay ku taliso xadiga maalin kasta ee hal giraam, waxay sheegtay in laba jeer xadiga ah uu ka badan yahay khatarta ee waxyeelada keeni karta.
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
Maarso 28 2020, FDA waxay soo saartay ogolaansho isticmaal xaalada degdeg ah oo hydroxychloroquine iyo chloroquine oo uu ogolaaday dhakhtarka daawaynaya dadka qaba COVID-19. Nuqulka 7aad ee tilmaamaha Jayna waxa sidoo kale ku jira interferon, ribavirin ama umifenovir in loo isticmaalo COVID-19.
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
Macluumaadka hordhaca ahi waxa uu muujinayaa in xadiga dare ee ribavirin lagu qaadanayo sanka ee SARS-CoV-2 ee vitro.
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
Nitrozoxanide ayaa lagu raliyay in mustaqbalka loo isticmaalo daraasada vivo kadib markii lagu arkay cuf yar oo neefsiga SARS-CoV-2 ah. Daraasado lagu sameeyay borootiinta hore ee kor u kacaysa ee protease-ka isku gudbinta xabka ee serane 2 (TMPRSS2) waxa uu daruuri u yahay gelitaanka SARS-CoV-2 ee isdhaxgalka qaadaha ACE2.
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Daraasada lagu sameeyay chloroquine iyo hydroxchloroquine iyada oo wadata ama aan wadan azithromycin waxa uu aad u xadiday in kahortaga bulshada caafimaadka ee lagu qadanaayo daawayntan iyada oo aan lagu samaynin daraasad. Oseltamivir ma xadido qaadashada SARS-CoV-2 vitro oo lama garanayo kaalinta ay ku leedahay daawaynta COVID-19.
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
Cyrokine duufaanada ah waxa ay noqon karaan mushkilad heerarka danbe ee COVID-19 aad u daran.
Cytokine storm can be a complication in the later stages of severe COVID-19.
Waxaa jira cadaymo ah in hydroxychloroquine ay yeelan karto kacsanaan anti-cytokine ah. Tocilizumab waxaa ay sidoo kale ku jiraa daawayntii tilmaamaha Gudida Caafimaadka Qaran ee Jayna kadib markii ay daraasadu dhamaystirantay.
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
Hadii wajiga socda ee 2 aanu noqon shaybaadh loo quri tuuray oo heer qaran ah oo Talyaaniga kadib markii la arkay ahaan najiiyada laga heley ah ee dadka qaba xanuunka daran.
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
Isku darka serum ferritin shaybaadhka dhiiga ee ah ee lagu ogaanayo cytokine duufaanka ah, waxa uu ka dhigan yahay shay lagula dagaalamo samaynsan, tas oo loo arko inay keento dhimasho dadka qaar qaaday.
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
Interleukin-6 qaadaha ah ee antagonist waxa ansixiyay FDA taas oo ku salaysan waxa keena ee daraasada daawaynta waxa keena isteeroodh cytokine ee ay soo saarto ee markaa keena caabuqa, CAR T unug ah ee daawyanta, 2017.
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
Ilaa iminka, ma jiraan wax iska yimid, cadayno xakamayn ee tocilizuman ah oo daawaynta caabuqa ee CRS.
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
Gudbinta antiboodhiga nadiifta ah iyo ka cufan ee lagu sameeyay nidaamka difaaca ee dadka kasoo ladnaanaya COVID-19 ee dadka u baahan ayaa lagu baadhayaa qaab aan talaal ahayn oo difaaca socda ah.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Khidadan waxaa lagu daweeyey SARS oo ay ku jirto natiijada aan dhamaystirnayn.
This strategy was tried for SARS with inconclusive results.
Muquuninta fayruska ee qaabka la doonayay ee ficilka daawaynta antiboodhiga hurda waxaa markaba loo gudbin karaa SARS-CoV-2.
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
Qaababka kale laakiin, sida antiboodhiga ku tiirsan cytotoxicity unuga iyo/ama phagocytosis, ayaa macquul ah.
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
Noocyada kale ee daawaynta anti boodhiga, tusaale ahaan, iyada oo la isticmaalayo monoclonal antiboodhiga, ayaa la samaynayaa.
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
Waxyaabaha convalescent ee serum, taas oo ka kooban qayb dareere ah oo dhiiga ah laga qaaday bukaanka oo ay ku jirto antiboodhi gaar ah oo fayrus, waxa uu kordhin karaa samaysanka dhakhsaha ah.
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
Xanuunka coronavirus, koox xanuuno ah oo aad iskugu dhaw
Coronavirus diseases, a group of closely related syndromes
Li Wenlian, dhakhtarka ka tirsan Isbitaalka Dhexe ee Wuhan, oo markii danbe qaaday una dhintay COVID-19 kadib markii uu sheegey safmarka fayruska.
Li Wenliang, a doctor at Central Hospital of Wuhan, who later contracted and died of COVID-19 after raising awareness of the spread of the virus.
Li Wenlian, dhakhtarka ka tirsan Isbitaalka Dhexe ee Wuhan, oo markii danbe qaaday una dhintay COVID-19 kadib markii uu sheegey safmarka fayruska.